Donepezil: Pharmacoeconomic implications of therapy

PharmacoEconomics

Volumn 16, Issue 1, 1999, Pages 99-114

  Foster, Rachel H ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Alzheimer's disease; Cost effectiveness; Donepezil; Pharmacoeconomics; Therapeutic use

Indexed keywords

DONEPEZIL;

ALZHEIMER DISEASE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DATA BASE; DRUG ACTIVITY; DRUG COST; DRUG FORMULATION; DRUG INFORMATION; DRUG USE; DRUG UTILIZATION; HEALTH CARE PLANNING; HOSPITALIZATION; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE; REVIEW; SOCIOECONOMICS; STATISTICAL ANALYSIS;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COSTS AND COST ANALYSIS; DRUG EVALUATION; ECONOMICS, PHARMACEUTICAL; HUMANS; INDANS; MARKOV CHAINS; NEW ZEALAND; NOOTROPIC AGENTS; PIPERIDINES;

EID: 0032797870     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199916010-00009     Document Type: Review

References (65)

1. 1. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry 1997 May; 154 (5 Suppl.): 1-39
2. 2. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997 Oct 22-29; 278: 1363-71
3. 3. Henke CJ, Burchmore MJ. The economic impact of tacrine in the treatment of Alzheimer's disease. Clin Ther 1997 Mar-Apr; 19: 330-45
4. 4. Baldereschi M, Di Carlo A, Amaducci L. Epidemiology of dementias. Drugs Today 1998; 34 (9): 747-58
5. 5. Hendric HC. Epidemiology of Alzheimer's disease. Geriatrics 1997 Sep; 52 Suppl. 2: S4-8
6. 6. Canadian Study of Health and Aging Working Group. Canadian study of health and aging: study methods and prevalence of dementia. Can Med Assoc J 1994; 150 (6): 899-913
7. 7. Molnar FJ, Dalziel WB. The pharmacoeconomics of dementia therapies: bringing the clinical, research and economic perspectives together. Drugs Aging 1997 Mar; 10: 219-33
8. 8. Meek PD, McKeithan EK, Schumock GT. Economic considerations in Alzheimer's disease. Pharmacotherapy 1998 MarApr; 18 (2 Pt 2): 68S-73S
9. 9. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's Disease revisited. Am J Public Health 1994 Aug; 84 (8): 1261-4
10. 10. Gray A, Fenn P. Alzheimer's disease: the burden of illness in England. Health Trend 1993; 25 (1): 31-7
11. 11. Greener M. Counting the cost of Alzheimer's disease. Inpharma 1999 Mar 20; 204: 3-4
12. 12. Hux MJ, O'Brien B, Iskedjian M, et al. Relation between severity of Alzheimer's disease and costs of caring. Can Med Assoc J 1998 Sep 8; 159: 457-65
13. 13. Souĉtre E, Thwaites RMA, Yeardley HL. Economic impact of Alzheimer's disease in the United Kingdom: cost of care and disease severity for non-institutionalised patients with Alzheimer's disease. Br J Psychiatry 1999; 174: 51-5
14. 14. Ernst RL, Hay JW, Fenn C, et al. Cognitive function and the costs of Alzheimer disease. Arch Neurol 1997 Jun; 54: 687-93
15. 15. Leon J, Cheng C-K, Neumann PJ. Alzheimer's disease care: costs and potential savings. Health Aff 1998 Nov-Dec; 17: 206-16
16. 16. Sramek JJ, Cutler NR. Recent developments in the drug treatment of Alzheimer's disease. Drugs Aging 1999 May; 14 (5): 359-73
17. 17. Unni LK. Beyond tacrine: recently developed cholinesterase inhibitors for the treatment of Alzheimer's disease. CNS Drugs 1998 Dec; 10 (6): 447-60
18. 18. Lovestone S, Graham N, Howard R. Guidelines on drug treatments for Alzheimer's disease. Lancet 1997 Jul 26; 350: 232-3
19. 19. Nordberg A, Svensson A-L. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf 1998 Dec; 19: 465-80
20. 20. Schachter AS, Davis KL. Guidelines for the appropriate use of cholinesterase inhibitors in patients with Alzheimer's disease. CNS Drugs 1999 Apr; 11 (4): 281-8
21. 21. Bryson HM, Benfield P. Donepezil. Drugs Aging 1997 Mar; 10: 234-9
22. 22. Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in Alzheimer's disease. Drugs Aging 1994; 4 (6): 510-40
23. 23. Rogers SL, Friedhoff LT, Donepezil SG. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a multicentre, randomized, double-blind, placebo controlled trial. Dementia 1996 Nov-Dec; 7: 293-303
24. 24. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998 May 11; 158: 1021-31
25. 25. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998 Jan; 50: 136-45
26. 26. Rogers SL, Friedhoff LT. Long term efficacy and safety of donepezil in the treatment of Alzheimer's disease; an interim analysis of the results of US multicentre open label extension study. Eur Neuropsychopharmacol 1998 Feb; 8: 67-75
27. 27. Barner EL, Gray SL, Donepezil use in Alzheimer disease. Ann Pharmacother 1998 Jan; 32: 70-7
28. 28. Shintani EY, Uchida KM. Donepezil: an anticholinesterase inhibitor for Alzheimer's disease. Am J Health System Pharm 1997 Dec 15; 54: 2805-10
29. 29. Maslow K, Whitehouse P. Defining and measuring outcomes in Alzheimer disease research: conference findings. Alz Dis Assoc Disord 1997; 11 Suppl. 6: 186-95
30. 30. Gwyther LP. The perspective of the person with Alzheimer disease: which outcomes matter in early to middle stages of dementia? Alz Dis Assoc Disord 1997; 11 Suppl. 6: 18-24
31. 31. Wood S, Cummings JL. Measuring outcomes in Alzheimer's disease research: assessment of the effectiveness of interventions. Dis Manage Health Outcomes 1999; 5 (1): 1-12
32. 32. Kane RL. Which outcomes matter in Alzheimer disease and who should define them? Alz Dis Assoc Disord 1997; 11 Suppl. 6: 12-7
33. 33. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease: results from a multinational trial. Dementia Geriatr Cogn Disord 1999; 10: 237-44
34. 34. Doody RS, Pratt RD, Perdomo CA. Clinical benefits of donepezil: results from a long term phase III extension trial [abstract]. Neurology 1990 Apr; 52 Suppl. 2: A174
35. 35. Pratt RD, Geldmacher D, Perdomo CA. An evaluation of the long term efficacy of donepezil in patients from a phase III clinical extension trial [abstract]. Neurology 1999 Apr; 52 Suppl. 2: A481-2
36. 36. Friedhoff LT, Rogers SL. Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer's disease [abstract]. Eur Neuropsychopharmacol 1997 Sep; 7 Suppl. 2: S246
37. 37. Winblad B, Hill S, Beermann B, et al. Issues in the economic evaluation of treatment for dementia: position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997; 11 Suppl. 3: 39-45
38. 38. Kaufer D, Catt K, Pollock B, et al. Assessing the effects of donepezil in Alzheimer's patients and its impact on caregivers [abstract]. J Am Geriatr Soc 1998 Sep; 46: S66
39. 39. McRae T, Relkin N, Knopman D. A large-scale, open-label trial of donepezil in the treatment of Alzheimer's disease [abstract]. Neurology 1998 Apr; 50 Suppl. 4: A90
40. 40. Post S, Whitehouse PJ. Emerging antidementia drugs: a preliminary ethical view. J Am Geriatr Soc 1998 Jun; 46: 784-7
41. 41. Geldmacher DS. Donepezil (Aricept) therapy for Alzheimer's disease. Compr Ther 1997 Jul; 23: 492-3
42. 42. Rogers SL, Friedhoff LT. Donepezil is well tolerated at clinically effective doses for the treatment of Alzheimer's disease [abstract]. Eur Neuropsychopharmacol 1997 Sep; 7 Suppl. 2: 251
43. 43. Salek SS, Walker MD, Bayer AJ. A review of quality of life in Alzheimer's disease. Part 2: issues in assessing drug effects. Pharmacoeconomics 1998 Dec; 14: 613-27
44. 44. Donepezil update. Drug Ther Bull 1998 Aug; 36: 60-1
45. 45. Small GW, Donohue JA, Brooks RL. An economic evaluation of donepezil in the treatment of Alzheimer's disease. Clin Ther 1998 Jul-Aug; 20: 838-50
46. 46. Max W. The cost of Alzheimer's disease: will drug treatment ease the burden? Pharmacoeconomics 1996 Jan; 9: 5-10
47. 47. Max W. Drug treatments for Alzheimer's disease: shifting the burden of care. CNS Drugs 1999 May; 11 (5): 363-72
48. 48. Busschbach JJV, Brouwer WBF, van der Donk A, et al. An outline for a cost-effectiveness analysis of a drug for patients with Alzheimer's disease. Pharmacoeconomics 1998 Jan; 13 (1 Pt 1): 21-34
49. 49. O'Brien BJ, Goeree R, Hux M, et al. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J Am Geriatr Soc 1999; 47 (5): 570-8
50. 50. Lanctot KL, Risebrough N, Oh PI. Factors affecting the economic attractiveness of cognitive enhancers in Alzheimer's disease [abstract]. J Clin Pharmacol 1998 Sep; 38: 870
51. 51. Neumann PJ, Hermann RC, Kuntz KM, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 1999; 52 (6): 1138-45
52. 52. Stewart A, Phillips R, Dempsey G. Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil. Int J Geriatr Psychiatry 1998; 13: 445-53
53. 53. Torrance GW, Feeny DH, Furlong WJ, et al. Multiattribute utility preference functions for a comprehensive health status classification system: Health Utilities Index Mark 2. Med Care 1996; 34: 707-22
54. 54. Neumann PJ, Hermann RC, Weinstein MC. Measuring QALYs in dementia. In: Wimo A, Karlsson G, Jönsson B, editors. Health economics in dementia. Chichester: Wiley, 1998
55. 55. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992 Feb 15; 146 (4): 473-81
56. 56. Milne RJ. Pharmacoeconomic models in disease management: a guide for the novice or perplexed. Dis Manage Health Outcomes 1998 Sep; 4 (3): 119-34
57. 57. Neumann PI, Hermann RC, Berenbaum PA, et al. Methods of cost-effectiveness analysis in the assessment of new drugs for Alzheimer's disease. Psychiatr Serv 1997 Nov; 48: 1440-4
58. 58. Wimo A, Karlsson G, Jönsson B, et al., editors. Health economics of dementia. Chichester: Wiley, 1998
59. 59. Robert P, Lebert F, Goni S, et al. The impact on caregiver distress of donepezil treatment of patients with mild Alzheimer's disease. Presented at the 152nd Annual Meeting of the American Psychiatric Association; 15-20 May 1999; Washington DC, USA
60. 60. Hollister L, Gruber N. Drug treatment of Alzheimer's disease: effects on caregiver burden and patient quality of life. Drugs Aging 1996 Jan; 8: 47-55
61. 61. Standing Medical Advisory Committee. The use of donepezil for Alzheimer's disease [online]. Department of Health; 1998 May 1. Available from: URL: http://www.doh.gov.UK/-donep.htm [accessed 1999 Feb 10]
62. 62. Knopman D, Schneider L, Davis K, et al. Long term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 1996 Jul; 47: 166-77
63. 63. Wimo A, Karlsson G, Nordberg A. Treatment of Alzheimer disease with tacrine: a cost-analysis model. Alz Dis Assoc Disord 1997 Dec; 11: 191-200
64. 64. Whitehouse PJ. Cholinesterase inhibitors in Alzheimer's disease: are they worth the cost? CNS Drugs 1999 Mar; 11 (3): 167-73
65. 65. Whitehouse PJ, Winblad B, Shostak D, et al. First international pharmacoeconomic conference on Alzheimer's disease: report and summary. Alz Dis Assoc Disord 1998; 12 (4): 266-80